Filing summary
Entity note: The request identifies Palvella Therapeutics, Inc., but the supplied Form 10-Q is for Pieris Pharmaceuticals, Inc. This summary covers Pieris’s quarter and nine months ended September 30, 2016; the entity discrepancy should be confirmed.
Business context and reporting period
Pieris is a clinical-stage biopharmaceutical company developing Anticalin protein-based drug candidates. It reported unaudited consolidated results for the three and nine months ended September 30, 2016, compared with the same 2015 periods. It had no product-sales revenue and expected none for the foreseeable future; reported revenue came primarily from collaborations and licensing.
Financial results and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $0.785 million | $0.415 million | $3.105 million | $0.792 million |
| Research and development | $4.622 million | $2.052 million | $12.781 million | $5.302 million |
| General and administrative | $2.341 million | $2.243 million | $6.677 million | $6.606 million |
| Net loss | $6.196 million | $3.922 million | $16.241 million | $11.157 million |
| Basic and diluted loss per share | $0.14 | $0.10 | $0.39 | $0.34 |
- At September 30, 2016, cash was $36.558 million, total current assets $41.137 million, total assets $43.713 million, total liabilities $12.230 million, and accumulated deficit $96.106 million. Cash was $29.349 million at December 31, 2015.
- Cash used in operating activities for the first nine months was $7.659 million, versus $10.213 million in 2015. Investing activities used $0.323 million; financing activities provided $15.221 million, principally from the 2016 private placement.
- The filing reports no debt balance at September 30, 2016; it reports no interest expense for the 2016 periods. Gross margin is not presented, and is not a useful product-sales measure given the absence of product revenue.
- Management stated existing cash was expected to fund operations and capital expenditure requirements for at least the next 12 months, while also stating that additional capital would be needed to continue operations and pursue business plans.
Material changes versus prior periods
- Nine-month revenue rose $2.313 million, mainly from recognition of the Roche upfront payment and Roche research services. The 2015 comparison included a Daiichi Sankyo milestone and government grant revenue; neither was recognized in the 2016 nine-month period.
- Nine-month R&D expense increased $7.480 million, driven by expanded preclinical, manufacturing and development work across PRS-060 and the 300-Series, additional personnel and other R&D costs. G&A was broadly stable at $6.677 million versus $6.606 million.
- Nine-month net loss widened to $16.241 million from $11.157 million, despite higher collaboration revenue, reflecting substantially higher R&D spending.
- Cash increased by $7.209 million from year-end 2015, supported by approximately $15.3 million of net proceeds from a June 2016 private placement. The placement issued common and convertible preferred shares and warrants, creating potential dilution.
Outlook, risks and unusual items
- Management expected continued substantial losses and increasing development spending. Its stated milestones included a Phase 1 trial for PRS-343 in the first half of 2017; PRS-060 Phase 1 initiation in the first half of 2017; PRS-080 Phase Ib dosing completion by the end of 2016 and a multiple-ascending-dose study thereafter; and selection of a PRS-332 candidate with IND-enabling work expected by year-end 2016. These are forward-looking plans, not results.
- The Roche collaboration included a $6.5 million upfront payment, recognized over performance obligations, and potential research funding, milestones and royalties. The filing states potential milestones of approximately $420.6 million, plus royalties; payments are contingent and not guaranteed.
- In October 2016, after quarter-end, Pieris reported achievement of a Daiichi Sankyo milestone following the decision to begin a non-human-primate GLP toxicity study; the amount is not specified in the supplied filing text. Also after quarter-end, it established a $35 million at-the-market equity program and reported no shares sold under it to date.
- Key risks include early-stage drug development and clinical or regulatory uncertainty, the need for additional funding, dependence on collaborators and third parties, and potential dilution or unfavorable financing terms. The company said risk factors had not materially changed from its 2015 Form 10-K.
- Management reported a material weakness in internal control over financial reporting involving technical accounting for complex transactions. An equity-transaction accounting error was corrected before the financial statements were issued; remediation was underway, including use of additional technical expertise as needed. Management nevertheless concluded the reported financial information was fairly presented in all material respects.
- The filing discusses ordinary-course claims and lawsuits but gives no specific case or clear quantified contingency value. It states that reserves or insurance are believed adequate, without assurance.
Important facts for investors to verify
- Confirm that Pieris Pharmaceuticals, Inc.—not Palvella Therapeutics, Inc.—is the intended issuer.
- Check progress against the stated 2016–2017 development timelines and assess clinical, manufacturing and regulatory updates.
- Review cash burn, the assumptions behind the stated 12-month cash runway, and the timing and terms of any additional financing or ATM sales.
- Verify recognition and remaining deferred balance of Roche collaboration revenue, as well as the conditions and collectability of future milestones and research funding.
- Monitor the Daiichi Sankyo milestone amount and the company’s remediation of the disclosed material weakness.